



14th July 2026
IOLCP/CGC/2026

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

Security Symbol: IOLCP

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Security Code: 524164

Subject: Approval from NMPA, China for Clopidogrel Bisulfate API

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Centre for Drug Evaluation (CDE) of the National Medical Products Administration (**NMPA**), **China**, has approved the Company's API product “**Clopidogrel Bisulfate**”, on 14th July 2026.

This approval is in addition to the valid Certificate of Suitability (CEP) already held by the Company for Clopidogrel Bisulfate, further strengthening the Company's regulatory portfolio and expanding its access to the Chinese pharmaceutical market.

This is for your information and records.

Thanking You,

Yours faithfully,
for **IOL Chemicals and Pharmaceuticals Limited**

Abhay Raj Singh
Sr. Vice President & Company Secretary